文献速递青光眼

EP2受体介导JV-GL1超长效降眼压作用

The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1.
PubMed 文献 · Br J Ophthalmol · 2020-11-25

该研究利用EP2受体基因敲除小鼠,探究JV-GL1长效降眼压机制。在类固醇诱导的高眼压模型中,EP2受体缺失完全消除了JV-GL1的初始1天及持续多天降眼压效应;而在野生型同窝对照小鼠中,JV-GL1显著降低眼压持续4-6天。结论表明JV-GL1的降眼压作用完全依赖EP2受体。

要点

  • JV-GL1在野生型高眼压小鼠中降眼压效果持续4-6天。
  • EP2受体敲除后JV-GL1的降眼压作用完全消失。
  • JV-GL1的短期与长效降眼压效应均依赖EP2受体。

核心结论

  • JV-GL1对眼压的1天及长期效应完全依赖于EP2受体。

研究设计与样本

  • 研究使用C57BL/6J和EP2受体敲除小鼠(B6.129-Ptger2tm1Brey/J),包括眼压正常和类固醇诱导高眼压模型。
  • 在全身麻醉下用眼压计测量眼压,离体用iPerfusion测量房水流出易度。

主要发现

  • 在类固醇诱导高眼压模型中,EP2受体基因缺失消除了JV-GL1初始1天及持续多天的降眼压效应。
  • 在野生型同窝对照高眼压小鼠中,JV-GL1显著降低眼压持续4-6天。

关键数值与推荐

  • 离体灌注100 nM脱酯化JV-GL1,或类固醇诱导高眼压小鼠提前3天局部使用0.01% JV-GL1。

临床怎么用

  • JV-GL1的超长效降眼压作用机制为靶向EP2受体,支持其作为EP2受体激动剂的开发。

局限性

  • 研究仅在小鼠模型中进行,未在非人灵长类或人类中验证EP2受体依赖性的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP2 receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP2 receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP2 receptors. METHODS: The protracted IOP reduction produced by JV-GL1 was investigated in C57BL/6J and EP2 receptor knock-out mice (B6.129-Ptger2tm1Brey /J; EP2KO). Both ocular normotensive and steroid-induced ocular hypertensive (SI-OHT) mice were studied. IOP was measured tonometrically under general anaesthesia. Aqueous humour outflow facility was measured ex vivo using iPerfusion in normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days prior. RESULTS: Both the initial 1-day and the protracted multiday effects of JV-GL1 in the SI-OHT model for glaucoma were abolished by deletion of the gene encoding the EP2 receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP2KO mice, but in littermate SI-OHT EP2WT control mice, JV-GL1 statistically significantly lowered IOP for 4-6 days. CONCLUSIONS: Both the 1-day and the long-term effects of JV-GL1 on IOP are entirely EP2 receptor dependent.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bertrand JA, Woodward DF, Sherwood JM, et al. The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1. Br J Ophthalmol. 2020. PMID: 33239414. doi:10.1136/bjophthalmol-2020-317762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。